Addex Therapeutics

Recent Finacing

Equity

Recent Raise

$42.7M

Addex Therapeutics discovers and develops orally available small-molecule allosteric modulators for neurological disorders, advancing mGluR5, mGluR2 and GABAB PAM/NAM candidates through clinical trials and collaborations.

Founded 2002

Geneve, Switzerland

11-50

Publicly Traded

addextherapeutics.com

Highlights

Focus Areas

Biotechnology

Health Care

Medical

Pharmaceutical

Financials

$42.7M

Total Raised

1

Funding round

Team

Upgrade to view the team

See the team members at Addex Therapeutics.